ALT
Altimmune Inc.
$3.38
$0.00(0.00%)
30
Overall
60
Value
9
Tech
23
Quality
Market Cap
$400.72M
Volume
2.03M
52W Range
$2.87 - $7.73
Target Price
$18.00
Company Overview
| Mkt Cap | $400.72M | Price | $3.38 |
| Volume | 2.03M | Change | +0.00% |
| P/E Ratio | -4.2 | Open | $3.34 |
| Revenue | $20.0K | Prev Close | $3.38 |
| Net Income | $-95.1M | 52W Range | $2.87 - $7.73 |
| Div Yield | N/A | Target | $18.00 |
| Overall | 30 | Value | 60 |
| Quality | 23 | Technical | 9 |
No chart data available
About Altimmune Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest News
Altamira Gold Adds Renowned Macro Investor Tavi Costa to Board
TipRanks Canadian Auto-Generated Newsdesk•a day ago
Gitlab, Altimmune, Cheniere, Pacific Biosciences, Hercules Shock Wall Street
TipRanks Weekend Auto-Generated Newsdesk•4 days ago
Alta Equipment Group Declares Quarterly Preferred Stock Dividend
TipRanks Auto-Generated Newsdesk•5 days ago
Alvarium Tiedemann Earnings Call: Growth Amid Heavy Noise
TipRanks Auto-Generated Newsdesk•5 days ago
Aeonian Launches First Drill Program at Jake Zone on Koocanusa Copper-Silver Project
TipRanks Canadian Auto-Generated Newsdesk•5 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ALT | $3.38 | 0% | 2.03M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |